switching from semaglutide to tirzepatide results Tirzepatide: What to Expect Switching Semaglutide to Tirzepatide |

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)

Characteristics include the presence of four pairs of flagella arising from a complicated system of axonemes and cysts that are ellipsoidal to ovoidal in shape

Maximum dose: 15 mg subcutaneously once a week

For patients with insurance coverage for GLP-1 therapies, choosing a weekly semaglutide or tirzepatide agent may provide the strongest metabolic support

The use of 6-flavor Rehmannia decoction with additives in the prevention of ototoxic deafness induced by gentamicin in guinea pigs